# DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/DMAC/diamedica-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-58a5078e
Ticker: DMAC
Company: DiaMedica Therapeutics
Source: DiaMedica Therapeutics
Published: 2026-07-17 20:30 EST
Original Source URL: https://www.diamedica.com/investors/press-releases/detail/1731/diamedica-announces-inducement-grants-under-nasdaq-listing
## Summary

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ...

## Article Body
MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on July 15, 2026, it granted options to purchase an aggregate of 160,000 shares of DiaMedica’s common stock to a newly hired non-executive employee whose employment commenced in July 2026. The stock options were a material inducement to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of their compensation.

The stock options were approved by the Compensation Committee of the Board of Directors and issued under the DiaMedica Therapeutics Inc. Amended and Restated 2021 Employment Inducement Incentive Plan. The options have an exercise price of $7.64 per share, which is equal to the closing price of the Company’s common stock on July 15, 2026, and are scheduled to vest and become exercisable, on a cumulative basis, with respect to 25% of such underlying shares on the one-year anniversary of the grant date and with respect to the remaining 75% of such underlying shares in 12 quarterly installments commencing three months after the one-year anniversary of the grant date, subject to the employee’s continued service with the Company. The options have a ten-year term.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction, and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information, visit the Company’s website at www.diamedica.com .

View source version on businesswire.com: https://www.businesswire.com/news/home/20260717319364/en/

Corporate Contact: Scott Kellen, Chief Financial Officer

(763) 496-5118 | skellen@diamedica.com

Investor Contact: Mike Moyer, Managing Director, LifeSci Advisors

mmoyer@lifesciadvisors.com

Media Contact: Madelin Hawtin, LifeSci Communications

mhawtin@lifescicomms.com

Source: DiaMedica Therapeutics Inc.

Released July 17, 2026
## Recent Company News
- 2026-07-17 20:30 EST — [DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/DMAC/diamedica-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-58a5078e) — Source: DiaMedica Therapeutics
- 2026-06-25 13:46 EST — [DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction](https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-announces-first-patients-dosed-in-phase-2-trial-of-dm199-for-the-treatment-of-fetal-growth-restriction) — Source: DiaMedica Therapeutics
- 2026-06-25 13:46 EST — [DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program](https://biopharmsignal.com/news/DMAC/diamedica-receives-fda-feedback-on-dm199-preeclampsia-nonclinical-program) — Source: DiaMedica Therapeutics
- 2026-06-25 13:46 EST — [DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026](https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-2026) — Source: DiaMedica Therapeutics
- 2026-06-25 13:46 EST — [DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial](https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-announces-75-enrollment-milestone-in-remedy2-phase-2-3-acute-ischemic-stroke-trial) — Source: DiaMedica Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)